AN ORAL, INFLAMMATION-TARGETING AND RESPONSIVE TACROLIMUS FORMULATION FOR THE TREATMENT OF STEROID-REFRACTORY AND STEROID-DEPENDENT INFLAMMATORY BOWEL DISEASE
$3,299,610FY2020Department of the ArmyDOD
Alivio Therapeutics Inc
Investigators
View source on USAspending →AN ORAL, INFLAMMATION-TARGETING AND RESPONSIVE TACROLIMUS FORMULATION FOR THE TREATMENT OF STEROID-REFRACTORY AND STEROID-DEPENDENT INFLAMMATORY BOWEL DISEASE · GrantIndex